Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939021 | 1.00 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13640177 | 1.00 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30256776 | 0.94 | CYP1A2 (0.44) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6296123 | 0.91 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1343403 | 0.91 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24214307 | 0.91 | CTSK (0.47) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3969261 | 0.90 | CTSK (0.50) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3732677 | 0.90 | CTSK (0.50) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29727300 | 0.90 | CTSK (0.50) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4416478 | 0.89 | CTSK (0.49) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| CN-119701002-A | Antibody drug conjugate, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4522622-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| WO-2004099171-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| EP-1458378-A1 | AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-6699898-B2 | METHOD OF TREATING CORONARY ARTERY DISEASE OR OTHER CETP-MEDIATED DISORDERS IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF ONE OF CLAIMS | PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT | 2004-03-02 | — | — | US | disclosed |
| WO-2003045378-A1 | AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1263716-A2 | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Pharmacor Inc. (CA) | 2002-12-11 | — | — | EP | disclosed |
| CN-1376143-A | Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES (JP) | 2002-10-23 | — | — | CN | disclosed |
| US-6455587-B1 | AROMATIC SULFONYL DERIVATIVES | PHARMACOR INC. (CA) | 2002-09-24 | — | — | US | disclosed |
| WO-2001068593-A2 | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PHARMACOR INC. (CA) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | CTSK 4670/4885CTSS 4634/4885CYP1A2 3362/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | CTSK 1186/4885CTSS 1259/4885CYP1A2 2253/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | CTSK 2205/4885CTSS 3593/4885CYP1A2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.